At a glance
ClinicalIndex Comparison Record- ✓Age 18-60 years
- ✓Meet DSM-5 criteria for at least moderate Cannabis Use Disorder with use on ≥20 of the last 28 days
- ✓Positive urine drug screen for cannabis at baseline visit
- ✓Express desire to quit cannabis
- ✕Pregnant or breastfeeding
- ✕Moderate or severe use disorder of any substance except nicotine
- ✕CNS-active medications
- ✕History of or current psychotic disorder or bipolar disorder
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder
In Brief
A Phase 2 clinical trial evaluating Active rTMS and Sham rTMS for Cannabis Use Disorder. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This investigation will preliminarily determine if a course of high-frequency rTMS applied to the left dorsolateral prefrontal cortex, will reduce behavioral craving, and fMRI cue-reactivity in treatment-seeking cannabis use disordered participants.
Study Details
Timeline
Interventions
rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.